Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in ASEAN has been steadily growing in recent years, driven by a combination of factors including an aging population, increasing prevalence of autoimmune diseases, and advancements in medical technology.
Customer preferences: Patients in ASEAN countries have shown a preference for biologic immunosuppressants over traditional drugs due to their effectiveness in treating autoimmune diseases. However, the high cost of biologics has led to a growing demand for biosimilars, which are expected to gain popularity in the region.
Trends in the market: The Immunosuppressants market in Indonesia has seen significant growth due to the high prevalence of autoimmune diseases in the country. The market is also driven by the government's efforts to improve healthcare infrastructure and increase access to medical treatments. In Thailand, the market is dominated by biologic drugs, with a particular focus on rheumatoid arthritis treatments. In Malaysia, the market is expected to see growth due to the increasing prevalence of autoimmune diseases and the government's efforts to improve healthcare access.
Local special circumstances: In the Philippines, the Immunosuppressants market is heavily influenced by the country's universal healthcare program, which has increased access to medical treatments for the population. However, the market is also characterized by a high degree of price sensitivity, with patients often opting for cheaper generic drugs over more expensive biologics. In Vietnam, the market is still in its early stages, with a focus on developing healthcare infrastructure and improving access to medical treatments.
Underlying macroeconomic factors: The Immunosuppressants market in ASEAN is influenced by a range of macroeconomic factors, including population growth, urbanization, and increasing healthcare spending. The region's aging population is also a key driver of market growth, as older individuals are more susceptible to autoimmune diseases. Additionally, advancements in medical technology have led to the development of new and more effective immunosuppressant drugs, which are expected to drive market growth in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
